Inclisiran lowers low-density lipoprotein (LLD “bad” cholesterol for up to one year in patients with high cardiovascular risk and elevated LDL cholesterol, according to late-breaking results from the ORION 1 trial presented today in a Hot Line LBCT Session at ESC Congress. “The ease of dosing – small volume subcutaneous injections twice a year most...